ADHD Therapeutics Market Size, Historical Analysis and Industry Growth with Double Digit CAGR by 2017-2024

Market Research Future
The Global ADHD Therapeutics Market report has been segmented on the basis of drug types which comprises of stimulants and non-stimulants. On the basis of distribution channels, market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

The Worldwide ADHD Therapeutics Market is segmented into four major regions such as: North America, Europe, and Asia-Pacific & Rest of the World. North America is estimated to dominate the global ADHD therapeutics market, with a maximum value share of the overall market. Followed by European region due to highly developed healthcare industry, high disposable income, ongoing clinical trials & early approval of drugs. However, Asia Pacific market is also witnessing a very strong growth due to high rate of development in healthcare industry, government initiatives for treatment of mental illness and increasing prevalence of mental disorders.

Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/1573 .

There are many big players in the ADHD Therapeutics Industry such as: Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical. ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood & often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviours or be hyperactive. As the ADHD Therapeutics Industry to be attractive worldwide, it’s growing and profitable, at the same time market has witnessed intense rivalry among existing competitors. Many new entrants expected to enter into ADHD Therapeutics Market.

Pipeline Development In ADHD:- Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage biopharmaceutical company focused on the development of innovative new products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two (2) proprietary, first-line medications, CTX-1301 (Dexmethylphenidate) and CTX-1302 (Dextroamphetamine), via the accelerated 505 (b)(2) regulatory pathway for the treatment of ADHD seeking indications for all patient segments: children, adolescents and adults. CTX-1301 and CTX-1302 utilize an innovative, flexible core tableting technology that enables the formulation and manufacturing of multi-cored tablets designed to deliver a rapid onset and last the entire active day while minimizing the afternoon crash and impact on sleep and appetite.

Growing paediatric population, increasing prevalence of ADHD, increasing awareness regarding ADHD are some of the factors responsible for the growth of the global ADHD therapeutics market. By seeing attractiveness of the market, market has witnessed, innovation followed by new launches. For example, Neos Therapeutics to launch Adzenys ER for ADHD in January 2018. FDA has approved Adzenys ER, an extended release oral suspension (amphetamine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients age 6 or older. Neos Therapeutics of Dallas and Fort Worth, Texas, announced in a statement that the company plans to launch Adzenys ER in January 2018. Neos Therapeutics is the only company than can offer both branded amphetamine and methylphenidate therapies in extended release dosage forms. When it is available in 2018, Adenzys ER oral suspension will be the third Neos extended release product for ADHD from the company. It needs no refrigeration or reconstitution at the pharmacy. Another form of the product, Adzenys XR-ODT, is a disintegrating tablet. This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended release amphetamine product and provides a different dosage form of companys already-approved Adzenys XR-ODT.

Order a Premium 80 Pages Copy Enabled with Respective Tables and Figures is Available @https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=1573 .

Major TOC of ADHD Therapeutics Market:

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

Ask Questions to Expertise @https://www.marketresearchfuture.com/enquiry/1573 .

….Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com